Ulla Feldt-Rasmussen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5221288/publications.pdf

Version: 2024-02-01

406 papers 16,605 citations

63 h-index 24179 110 g-index

460 all docs

460 docs citations

460 times ranked 13498 citing authors

#	Article	IF	CITATIONS
1	Sex difference in patients with controlled acromegaly—A multicentre survey. Clinical Endocrinology, 2023, 98, 74-81.	1.2	6
2	Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Seminars in Cancer Biology, 2022, 79, 141-162.	4.3	18
3	Multiple endocrine neoplasia type 2: A review. Seminars in Cancer Biology, 2022, 79, 163-179.	4.3	32
4	Thyroid Disease and Hepatocellular Carcinoma Survival: A Danish Nationwide Cohort Study. Gastrointestinal Tumors, 2022, 9, 37-42.	0.3	0
5	Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms. PLoS ONE, 2022, 17, e0262898.	1.1	3
6	Severe weight loss in a hypothyroid patient as an acute presentation of autoimmune polyglandular syndrome type II. Hormones, 2022, 21, 317-322.	0.9	2
7	Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. European Journal of Endocrinology, 2022, 186, 687-700.	1.9	12
8	Approach to the Patient With Glucocorticoid-induced Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2065-2076.	1.8	14
9	Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: A systematic review and metaâ€analysis. Clinical Endocrinology, 2022, 97, 519-531.	1.2	4
10	Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis. Lancet Diabetes and Endocrinology,the, 2022, 10, 243-252.	5.5	49
11	Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1906-1919.	1.8	12
12	Hearing loss in fabry disease: A 16Âyear follow-up study of the Danish nationwide cohort. Molecular Genetics and Metabolism Reports, 2022, 31, 100841.	0.4	4
13	Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes. Frontiers in Endocrinology, 2022, 13, 857504.	1.5	2
14	The rate of empty sella (ES) in traumatic brain injury: Links with endocrine profiles., 2022,, 325-339.		0
15	Association of Thyroid Peroxidase Antibodies and Thyroglobulin Antibodies with Thyroid Function in Pregnancy: An Individual Participant Data Meta-Analysis. Thyroid, 2022, 32, 828-840.	2.4	12
16	The Influence of Triclosan on the Thyroid Hormone System in Humans - A Systematic Review. Frontiers in Endocrinology, 2022, 13, .	1.5	4
17	Education and Income Do Not Impact Temporal Trends of Papillary and Follicular Thyroid Cancer Incidence in Denmark—But What Does?. Clinical Thyroidology, 2022, 34, 253-255.	0.0	0
18	Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis: analysis of the KIMS database. European Journal of Endocrinology, 2022, 187, 373-381.	1.9	2

#	Article	IF	CITATIONS
19	Sex differences in acromegaly at diagnosis: A nationwide cohort study and metaâ€analysis of the literature. Clinical Endocrinology, 2021, 94, 625-635.	1.2	21
20	The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments. Endocrine, 2021, 71, 467-475.	1.1	6
21	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1183-e1194.	1.8	48
22	Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2251-e2261.	1.8	38
23	Thyroid Function Had No Impact on Physical Activity in Individuals Aged 46–89 Years from a General Dutch Population. Clinical Thyroidology, 2021, 33, 55-57.	0.0	0
24	Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO. Endocrine Connections, 2021, 10, 316-324.	0.8	17
25	Levothyroxine Therapy in Elderly Patients With Hypothyroidism. Frontiers in Endocrinology, 2021, 12, 641560.	1.5	24
26	Thyroid Dysfunction Remains Uncommon Despite a High Prevalence of Thyroid Antibodies 22 Years After Starting Iodine Fortification in Sri Lanka. Clinical Thyroidology, 2021, 33, 157-159.	0.0	0
27	Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial. ELife, 2021, 10, .	2.8	22
28	Off-label treatment with Pasireotide and use of continuous glucose monitoring in late familial hyperinsulinemic hypoglycemia: a case report. Acta Diabetologica, 2021, 58, 1123-1125.	1.2	2
29	Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. Molecular Genetics and Metabolism, 2021, 132, 234-243.	0.5	10
30	The hypothalamus-pituitary-thyroid (HPT)-axis and its role in physiology and pathophysiology of other hypothalamus-pituitary functions. Molecular and Cellular Endocrinology, 2021, 525, 111173.	1.6	31
31	MiR-122-5p: A Novel Biomarker of Glucocorticoid Action. Journal of the Endocrine Society, 2021, 5, A89-A89.	0.1	0
32	Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity. Journal of the Endocrine Society, 2021, 5, A64-A65.	0.1	4
33	POS0313â€INCIDENCE AND PREVALENCE OF POLYAUTOIMMUNITY IN SEROPOSITIVE COMPARED WITH SERONEGATIVE PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONWIDE COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 382.2-383.	0.5	0
34	Alexithymia, Emotional Distress, and Perceived Quality of Life in Patients With Hashimoto's Thyroiditis. Frontiers in Psychology, 2021, 12, 667237.	1.1	15
35	Brain Tumours Involving the Areas of the Circadian System Result in Disturbances in Melatonin Secretion, Fatigue and Poor Quality of Life. Journal of the Endocrine Society, 2021, 5, A710-A710.	0.1	0
36	Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Scientific Reports, 2021, 11, 13153.	1.6	147

#	Article	IF	Citations
37	Thyroid Function Tests During Hospitalization for SARS-CoV-2 Infection Revisited. Clinical Thyroidology, 2021, 33, 254-256.	0.0	0
38	Pituitary function after transsphenoidal surgery including measurement of basal morning cortisol as predictor of adrenal insufficiency. Endocrine Connections, 2021, 10, 750-757.	0.8	10
39	Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary, 2021, 24, 887-903.	1.6	21
40	Thyroid-Stimulating Hormone Receptor Antibodies in Refractory Graves' Disease Change Differently According to the Type of Definitive Therapy Administered. Clinical Thyroidology, 2021, 33, 350-353.	0.0	0
41	Brain tumours in children and adolescents may affect the circadian rhythm and quality of life. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 3376-3386.	0.7	5
42	Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. Molecular Genetics and Metabolism Reports, 2021, 28, 100786.	0.4	14
43	Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. Journal of Medical Genetics, 2021, 58, 692-700.	1.5	13
44	Surgical Preservation of Parathyroid Function During Total Thyroidectomy Can Be Improved by Intraoperative Imaging. Clinical Thyroidology, 2021, 33, 456-458.	0.0	0
45	Brain tumours result in sleep disorders in children and adolescents. Sleep Medicine, 2021, 88, 13-21.	0.8	6
46	Biotin Use Can Interfere with the Management of Thyroid Diseases, Including Thyroid Cancer. Clinical Thyroidology, 2021, 33, 520-522.	0.0	0
47	Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case–control study. Nephrology Dialysis Transplantation, 2020, 35, 2191-2197.	0.4	12
48	Semen quality in hypogonadal acromegalic patients. Pituitary, 2020, 23, 160-166.	1.6	6
49	Comment on: Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis—prevalence and clinical approach: reply. Rheumatology, 2020, 59, e78-e78.	0.9	1
50	Ecological momentary assessments (EMAs) did not improve responsiveness of patient-reported outcomes on quality of life. Journal of Clinical Epidemiology, 2020, 125, 138-147.	2.4	1
51	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2020, 131, 219-228.	0.5	44
52	SAT-505 Non-Adherence to Levothyroxine Treatment, a Condition Not to Be Ignored nor Forgotten, Should Be Assessed by Thyroxine Absorption Test. Journal of the Endocrine Society, 2020, 4, .	0.1	0
53	Hashimoto's thyroiditis as a risk factor for thyroid cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 364-371.	1.2	33
54	Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype. Molecular Genetics and Metabolism Reports, 2020, 25, 100670.	0.4	6

#	Article	IF	CITATIONS
55	Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment. Case Reports in Medicine, 2020, 2020, 1-3.	0.3	9
56	Fluispotter, a novel automated and wearable device for accurate volume serial dried blood spot sampling. Bioanalysis, 2020, 12, 665-681.	0.6	4
57	Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatmentÂfor early breast cancer. PLoS ONE, 2020, 15, e0230681.	1.1	38
58	Baseline patient characteristics of followME, a new, patient-centric, prospective, observational Fabry disease registry that evaluates migalastat, ERT, and a natural history cohort. Molecular Genetics and Metabolism, 2020, 129, S150.	0.5	0
59	Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis—prevalence and clinical approach. Rheumatology, 2020, 59, 2764-2773.	0.9	21
60	Cardiomyopathy and kidney function in agalsidase betaâ€treated female Fabry patients: a preâ€treatment vs. postâ€treatment analysis. ESC Heart Failure, 2020, 7, 825-834.	1.4	13
61	Shorter Recall Period for the Thyroid-Related Patient-Reported Outcome Measure ThyPRO Did Not Change the Accuracy as Evaluated by Repeated Momentary Measurements. Thyroid, 2020, 30, 185-191.	2.4	2
62	Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. Obstetrical and Gynecological Survey, 2020, 75, 10-12.	0.2	4
63	Phenotypic and genotypic features of a large kindred with a germline AIP variant. Clinical Endocrinology, 2020, 93, 146-153.	1.2	3
64	Is the alphaâ€galactosidase A variant <scp>p.Asp313Tyr</scp> (<scp>p.D313Y</scp>) pathogenic for Fabry disease? A systematic review. Journal of Inherited Metabolic Disease, 2020, 43, 922-933.	1.7	16
65	Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis. Lancet Diabetes and Endocrinology,the, 2020, 8, 501-510.	5.5	130
66	Genotype–phenotype associations in PPGLs in 59 patients with variants in SDHX genes. Endocrine Connections, 2020, 9, 793-803.	0.8	3
67	Neuroendocrine Aspects. , 2020, , 381-391.		0
68	MON-179 Association Between Long-Term Prednisolone Induced Adrenal Insufficiency and Polymorphisms in the Glucocorticoid Receptor Gene. Journal of the Endocrine Society, 2020, 4, .	0.1	1
69	Glucocorticoid-induced adrenal suppression and metabolic syndrome in glucocorticoid treated AECOPD patients related to different gene polymorphisms of the glucocorticoid receptor gene. , 2020, , .		0
70	Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth. JAMA - Journal of the American Medical Association, 2019, 322, 632.	3.8	224
71	Thyroid Peroxidase Antibodies and Prospective Live Birth Rate: A Cohort Study of Women with Recurrent Pregnancy Loss. Thyroid, 2019, 29, 1465-1474.	2.4	43
72	Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Realâ€World Data. Clinical Pharmacology and Therapeutics, 2019, 106, 925-926.	2.3	4

#	Article	IF	Citations
73	Risk of Thyroid Cancer in 1,504 Patients Referred for Thyroid Surgery with Assumed Benign Histology. European Thyroid Journal, 2019, 8, 246-255.	1.2	3
74	Hippocampal Volume, Cognitive Functions, Depression, Anxiety, and Quality of Life in Patients With Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4563-4577.	1.8	28
75	Nutraceutical Supplements in the Thyroid Setting: Health Benefits beyond Basic Nutrition. Nutrients, 2019, 11, 2214.	1.7	29
76	Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997–2013: a nationwide study. Clinical Epidemiology, 2019, Volume 11, 93-99.	1.5	7
77	Thoughts on the Japanese and American Perspectives on Thyroid Storm. Thyroid, 2019, 29, 1033-1035.	2.4	3
78	Design of a prospective, multicenter, multinational, observational safety and outcomes registry in Fabry disease patients treated with migalastat and untreated patients. Molecular Genetics and Metabolism, 2019, 126, S140-S141.	0.5	0
79	Significant abdominal and acute pain improvements in young patients with Fabry disease initiated on agalsidase beta treatment before age 30: A Fabry registry analysis. Molecular Genetics and Metabolism, 2019, 126, S74.	0.5	O
80	Clinical outcomes after switching to migalastat from agalsidase alfa or agalsidase beta in patients with Fabry disease: Post hoc analysis from ATTRACT. Molecular Genetics and Metabolism, 2019, 126, S141.	0.5	0
81	Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Clinical and Translational Radiation Oncology, 2019, 15, 93-98.	0.9	2
82	Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study. American Journal of Medical Genetics, Part A, 2019, 179, 1069-1073.	0.7	13
83	Renal and cardiac outcomes of young male patients with Fabry disease initiated on agalsidase beta treatment before age 30: A Fabry registry analysis. Molecular Genetics and Metabolism, 2019, 126, S73-S74.	0.5	O
84	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2019, 126, S53.	0.5	1
85	Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment. PLoS ONE, 2019, 14, e0225071.	1.1	9
86	Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study. Nephrology Dialysis Transplantation, 2019, 34, 1525-1533.	0.4	23
87	Thyroglobulin and Tg Antibodies. , 2019, , 655-671.		O
88	Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997–2014: A Nationwide Study. Thyroid, 2019, 29, 368-377.	2.4	43
89	Thyroid and Infertility. , 2019, , 752-761.		0
90	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism, 2019, 126, 224-235.	0.5	65

#	Article	IF	Citations
91	MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD). Journal of the Endocrine Society, 2019, 3, .	0.1	1
92	Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study. Endocrine Connections, $2019, 8, 1-7$.	0.8	11
93	Change in baseline characteristics over 20 years of adults with growth hormone (GH) deficiency on GH replacement therapy. European Journal of Endocrinology, 2019, 181, 629-638.	1.9	9
94	Renal and cardiac outcomes in female patients with Fabry disease treated with agalsidase beta: A Fabry registry analysis of pre-versus post-treatment comparison. Molecular Genetics and Metabolism, 2019, 126, S150.	0.5	0
95	SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS). Journal of the Endocrine Society, 2019, 3, .	0.1	0
96	SUN-343 Mortality in Pheochromocytoma after Radical Surgery: Danish National Data over a Period of 40 Years. Journal of the Endocrine Society, 2019, 3, .	0.1	0
97	Maternal exposure to UV filters: associations with maternal thyroid hormones, IGF-I/IGFBP3 and birth outcomes. Endocrine Connections, 2018, 7, 334-346.	0.8	18
98	Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. European Journal of Endocrinology, 2018, 178, 491-499.	1.9	47
99	Cognitive Impairments and Subjective Cognitive ComplaintsÂin Fabry Disease: A Nationwide Study andÂReview ofÂtheÂLiterature. JIMD Reports, 2018, 41, 73-80.	0.7	19
100	Thyroglobulin and Thyroglobulin Antibodies. , 2018, , 65-91.		0
101	New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 523-531.	1.8	24
102	Determination of thyroid hormones in placenta using isotope-dilution liquid chromatography quadrupole time-of-flight mass spectrometry. Journal of Chromatography A, 2018, 1534, 85-92.	1.8	25
103	Semen quality in patients with pituitary disease and adult-onset hypogonadotropic hypogonadism. Endocrine Connections, 2018, 7, 523-533.	0.8	9
104	Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. European Journal of Endocrinology, 2018, 178, 65-74.	1.9	18
105	Chronic endocrine consequences of traumatic brain injury â€" what is the evidence?. Nature Reviews Endocrinology, 2018, 14, 57-62.	4.3	33
106	Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors. Chronobiology International, 2018, 35, 368-377.	0.9	5
107	Conversion of standard retrospective patient-reported outcomes to momentary versions: cognitive interviewing reveals varying degrees of momentary compatibility. Quality of Life Research, 2018, 27, 1065-1076.	1.5	7
108	Drug Effects and Thyroid Function. , 2018, , 772-779.		2

#	Article	IF	CITATIONS
109	SP015SUCCESSFUL OUTCOME OF PREGNANCY IN A SEVERLY AFFECTED FEMALE PATIENT WITH FABRY DISEASE COMPLICATED BY PRE-ECLAMPSIA: CLINICAL MANAGEMENT AND PLACENTAL EXAMINATION. Nephrology Dialysis Transplantation, 2018, 33, i351-i352.	0.4	O
110	Adaptation and cross-cultural validation of the Spanish version of the Thyroid-Related Quality-of-Life Patient-Reported Outcome questionnaire. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 500-507.	0.1	7
111	Adaptation and cross-cultural validation of the Spanish version of the Thyroid-Related Quality-of-Life Patient-Reported Outcome questionnaire. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2018, 65, 500-507.	0.1	O
112	Less known aspects of central hypothyroidism: Part 1 $\hat{a} \in$ "Acquired etiologies. Journal of Clinical and Translational Endocrinology, 2018, 14, 25-33.	1.0	12
113	No evidence of increased risk of thyroid dysfunction in well treated people living with HIV. Aids, 2018, 32, 2195-2199.	1.0	12
114	Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine, 2018, 62, 737-739.	1.1	21
115	Less known aspects of central hypothyroidism: Part 2 – Congenital etiologies. Journal of Clinical and Translational Endocrinology, 2018, 14, 5-11.	1.0	6
116	How Should Thyroid-Related Quality of Life Be Assessed? Recalled Patient-Reported Outcomes Compared to Here-and-Now Measures. Thyroid, 2018, 28, 1561-1570.	2.4	13
117	Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901–2014: a nationwide study. Clinical Epidemiology, 2018, Volume 10, 1479-1487.	1.5	19
118	Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions. Endocrine, 2018, 62, 519-527.	1.1	5
119	Association of In Utero Persistent Organic Pollutant Exposure With Placental Thyroid Hormones. Endocrinology, 2018, 159, 3473-3481.	1.4	46
120	Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960–2014: a nationwide study. Endocrine Connections, 2018, 7, 829-839.	0.8	32
121	Thyroid Autoimmunity., 2018, , 636-650.		O
122	Patients with Benign Thyroid Diseases Experience an Impaired Sex Life. Thyroid, 2018, 28, 1261-1269.	2.4	10
123	Thyroid Function and Depression. , 2018, , 792-801.		1
124	2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. European Thyroid Journal, 2018, 7, 225-237.	1.2	135
125	Maternal thyroid disorder in pregnancy and risk of cerebral palsy in the child: a population-based cohort study. BMC Pediatrics, 2018, 18, 181.	0.7	11
126	Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet Journal of Rare Diseases, 2018, 13, 68.	1.2	23

#	Article	IF	CITATIONS
127	ThyPROgr: the Greek edition of the ThyPRO questionnaires for patients with benign thyroid diseases. Hormones, 2018, 17, 107-112.	0.9	4
128	Enzyme Replacement Therapy During Pregnancy in Fabry Patients. JIMD Reports, 2018, 44, 93-101.	0.7	5
129	Pheochromocytoma in Denmark during 1977–2016: validating diagnosis codes and creating a national cohort using patterns of health registrations. Clinical Epidemiology, 2018, Volume 10, 683-695.	1.5	7
130	The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease in 2 Danish families. Molecular Genetics and Metabolism, 2018, 123, S44.	0.5	1
131	European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism, 2018, 124, 189-203.	0.5	122
132	Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2182-2188.	1.8	98
133	SP018AGE RELATED ATTRITION OF RENAL FUNCTION IN FABRY DISEASE PATIENTS ON ENZYME REPLACEMENT THERAPY: LONG-TERM OBSERVATION IN A NATIONWIDE, FAMILY-SCREENED COHORT BASED ON CR-EDTA CLEARANCE COMPARED WITH RENAL HEALTHY POPULATION. Nephrology Dialysis Transplantation, 2018, 33, i352-i353.	0.4	0
134	PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open, 2018, 8, e019487.	0.8	5
135	The Romanian Version of the Thyroid-Related Patient-Reported Outcomes Thypro and Thypro-39. Translation and Assessment of Reliability and Crosscultural Validity. Acta Endocrinologica, 2018, 14, 192-200.	0.1	8
136	Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy. Neuromuscular Disorders, 2017, 27, 358-362.	0.3	6
137	Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort. Acta Oncológica, 2017, 56, 415-421.	0.8	22
138	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Journal of Medical Genetics, 2017, 54, 288-296.	1.5	262
139	Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study. Endocrine-Related Cancer, 2017, 24, L39-L42.	1.6	32
140	Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. JIMD Reports, 2017, 38, 45-51.	0.7	18
141	Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study. Scandinavian Cardiovascular Journal, 2017, 51, 207-216.	0.4	14
142	Response of patients with Fabry disease with the amenable GLA mutation p.N215S to treatment with migalastat. Molecular Genetics and Metabolism, 2017, 120, S68-S69.	0.5	0
143	Efficacy and safety of migalastat, an oral pharmacologic chaperone for Fabry disease: results from two randomized phase 3 studies, FACETS and ATTRACT. Molecular Genetics and Metabolism, 2017, 120, S45-S46.	0.5	1
144	Fabry disease: renal function during long-term enzyme replacement therapy evaluated by gold standard GFR 51Cr-EDTA clearance. Molecular Genetics and Metabolism, 2017, 120, S90.	0.5	0

#	Article	IF	Citations
145	Increase in thyroglobulin antibody and thyroid peroxidase antibody levels, but not preterm birth-rate, in pregnant Danish women upon iodine fortification. European Journal of Endocrinology, 2017, 176, 603-612.	1.9	18
146	Founder Effect of the <i>RET^{C611Y}</i> Mutation in Multiple Endocrine Neoplasia 2A in Denmark: A Nationwide Study. Thyroid, 2017, 27, 1505-1510.	2.4	16
147	The D313Y variant in the <i>GLA</i> gene – no evidence of a pathogenic role in Fabry disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 617-621.	0.6	19
148	Intrachiasmatic abscess caused by IgG4-related hypophysitis. Acta Neurochirurgica, 2017, 159, 2229-2233.	0.9	13
149	Is Thyroid Replacement Therapy Necessary in Fertility Patients with "Normal―TSH?. Journal of Fetal Medicine, 2017, 4, 171-176.	0.1	0
150	Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. European Journal of Endocrinology, 2017, 177, 287-295.	1.9	50
151	Fabry Disease in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
152	Distribution of <i>RET</i> Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994–2014: A Nationwide Study. Thyroid, 2017, 27, 215-223.	2.4	29
153	THU0340â€Adrenal insufficiency during glucocorticoid treatment in patients with polymyalgia reumatica or giant cell arteritis. , 2017, , .		0
154	Diagnosis of Hypothyroidism. , 2017, , 604-607.		0
155	Association between Hashimoto's Thyroiditis and Thyroid Cancer in 64,628 Patients. Frontiers in Oncology, 2017, 7, 53.	1.3	104
156	Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. Frontiers in Endocrinology, 2017, 8, 179.	1.5	20
157	Causes of Hypothyroidism. , 2017, , 600-603.		0
158	Evaluation of ICD-10 algorithms to identify hypopituitary patients in the Danish National Patient Registry. Clinical Epidemiology, 2017, Volume 9, 75-82.	1.5	2
159	Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Research, 2017, 6, 1776.	0.8	87
160	Polysomnographic findings in craniopharyngioma patients. Sleep and Breathing, 2017, 21, 975-982.	0.9	14
161	The flame retardant DE-71 (a mixture of polybrominated diphenyl ethers) inhibits human differentiated thyroid cell function in vitro. PLoS ONE, 2017, 12, e0179858.	1.1	18
162	Ghrelin-mediated inhibition of the TSH-stimulated function of differentiated human thyrocytes ex vivo. PLoS ONE, 2017, 12, e0184992.	1.1	12

#	Article	IF	Citations
163	Thyroiditis, Infectious and Subacute. , 2017, , 737-745.		0
164	High Level of Agreement between Electronic and Paper Mode of Administration of a Thyroid-Specific Patient-Reported Outcome, ThyPRO. European Thyroid Journal, 2016, 5, 65-72.	1.2	16
165	Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: Results from the placebo-controlled, randomized AMIO-CAT trial. European Journal of Internal Medicine, 2016, 33, 36-41.	1.0	9
166	Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. New England Journal of Medicine, 2016, 375, 545-555.	13.9	390
167	Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients. Endocrine, 2016, 54, 15-23.	1.1	32
168	Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study. Thyroid, 2016, 26, 1010-1018.	2.4	55
169	Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 988-998.	1.8	24
170	Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. European Journal of Endocrinology, 2016, 175, 181-190.	1.9	148
171	Hashimoto's encephalopathy: A rare proteiform disorder. Autoimmunity Reviews, 2016, 15, 466-476.	2.5	74
172	Migration of phthalates on culture plates $\hat{a}\in$ an important challenge to consider for in vitro in vitro in vitro in vitro in vitro in 2016, 76, 165-171.	0.6	1
173	Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In Vitro. PLoS ONE, 2016, 11, e0151192.	1.1	11
174	Effects of the Commercial Flame Retardant Mixture DE-71 on Cytokine Production by Human Immune Cells. PLoS ONE, 2016, 11, e0154621.	1.1	14
175	Disease-Specific as Well as Generic Quality of Life Is Widely Impacted in Autoimmune Hypothyroidism and Improves during the First Six Months of Levothyroxine Therapy. PLoS ONE, 2016, 11, e0156925.	1.1	109
176	Fabry disease, respiratory symptoms, and airway limitation – a systematic review. European Clinical Respiratory Journal, 2015, 2, 26721.	0.7	20
177	Hypopituitarism in Traumatic Brain Injury—A Critical Note. Journal of Clinical Medicine, 2015, 4, 1480-1497.	1.0	29
178	Influence of Phthalates on in vitro Innate and Adaptive Immune Responses. PLoS ONE, 2015, 10, e0131168.	1.1	38
179	Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up. PLoS ONE, 2015, 10, e0143940.	1.1	18
180	Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1301-14.	1.4	57

#	Article	IF	Citations
181	Ophthalmic experience over 10Âyears in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement. Acta Ophthalmologica, 2015, 93, 258-264.	0.6	26
182	Exploring the Experiences of People With Hypo- and Hyperthyroidism. Qualitative Health Research, 2015, 25, 945-953.	1.0	23
183	Increased risk of thyroid autoimmunity in rheumatoid arthritis. Endocrine, 2015, 50, 4-5.	1.1	8
184	Patient reported outcome in posttraumatic pituitary deficiency: results from The Danish National Study on posttraumatic hypopituitarism. European Journal of Endocrinology, 2015, 172, 753-762.	1.9	17
185	Early endocrine alterations reflect prolonged stress and relate to 1-year functional outcome in patients with severe brain injury. European Journal of Endocrinology, 2015, 172, 813-822.	1.9	25
186	Thyroid-specific questions on work ability showed known-groups validity among Danes with thyroid diseases. Quality of Life Research, 2015, 24, 1615-1627.	1.5	6
187	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases, 2015, 10, 36.	1.2	239
188	Quality of Life in Patients with Benign Nontoxic Goiter: Impact of Disease and Treatment Response, and Comparison with the General Population. Thyroid, 2015, 25, 284-291.	2.4	54
189	Thyroid function and autoimmunity in Danish pregnant women after an iodine fortification program and associations with obstetric outcomes. European Journal of Endocrinology, 2015, 173, 709-718.	1.9	25
190	Development of a Short Version of the Thyroid-Related Patient-Reported Outcome ThyPRO. Thyroid, 2015, 25, 1069-1079.	2.4	82
191	Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues $\hat{a} \in \mathbb{C}^n$. Observations in two patients with acromegaly and severe headache. Growth Hormone and IGF Research, 2015, 25, 262-267.	0.5	23
192	Cross-cultural validity of the thyroid-specific quality-of-life patient-reported outcome measure, ThyPRO. Quality of Life Research, 2015, 24, 769-780.	1.5	52
193	Influence of Phthalates on Cytokine Production in Monocytes and Macrophages: A Systematic Review of Experimental Trials. PLoS ONE, 2015, 10, e0120083.	1.1	35
194	Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?. Current Medicinal Chemistry, 2015, 22, 2801-2809.	1.2	12
195	Confirmatory factor analysis of the thyroid-related quality of life questionnaire ThyPRO. Health and Quality of Life Outcomes, 2014, 12, 126.	1.0	41
196	The Thyroid-Related Quality of Life Measure ThyPRO Has Good Responsiveness and Ability to Detect Relevant Treatment Effects. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3708-3717.	1.8	123
197	Corrigendum to "Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself―[Eur J Intern Med, 24 (8), 714–720]. European Journal of Internal Medicine, 2014, 25, 781-783.	1.0	3
198	Sleep–wake and melatonin pattern in craniopharyngioma patients. European Journal of Endocrinology, 2014, 170, 873-884.	1.9	56

#	Article	IF	Citations
199	Development and implementation of PROgmatic: A clinical trial management system for pragmatic multi-centre trials, optimised for electronic data capture and patient-reported outcomes. Clinical Trials, 2014, 11, 344-354.	0.7	26
200	Few items in the thyroid-related quality of life instrument ThyPRO exhibited differential item functioning. Quality of Life Research, 2014, 23, 327-338.	1.5	29
201	Prevalence of Posttraumatic Growth Hormone Deficiency Is Highly Dependent on the Diagnostic Set-up: Results From The Danish National Study on Posttraumatic Hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 101-110.	1.8	64
202	Primary Hyperparathyroidism in Young People. When Should We Perform Genetic Testing for Multiple Endocrine Neoplasia 1 (MEN-1)?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3983-3987.	1.8	39
203	Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease. Nephrology Dialysis Transplantation, 2014, 29, 619-625.	0.4	26
204	Gestational age-specific reference ranges from different laboratories misclassify pregnant women's thyroid status: comparison of two longitudinal prospective cohort studies. European Journal of Endocrinology, 2014, 170, 329-339.	1.9	42
205	Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. Clinical Endocrinology, 2014, 80, 92-100.	1.2	13
206	DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. European Journal of Endocrinology, 2014, 171, R33-R46.	1.9	94
207	Increased Risk of Long-Term Sickness Absence, Lower Rate of Return to Work, and Higher Risk of Unemployment and Disability Pensioning for Thyroid Patients: A Danish Register-Based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3184-3192.	1.8	43
208	Giant prolactinomas in women. European Journal of Endocrinology, 2014, 170, 31-38.	1.9	64
209	The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials, 2014, 15, 115.	0.7	60
210	Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2018-2029.	1.8	31
211	Myxoedema coma: an almost forgotten, yet still existing cause of multiorgan failure. BMJ Case Reports, 2014, 2014, bcr2013203223-bcr2013203223.	0.2	17
212	Anxiety and Depression Are More Prevalent in Patients with Graves' Disease than in Patients with Nodular Goitre. European Thyroid Journal, 2014, 3, 173-178.	1.2	40
213	Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma. Current Medicinal Chemistry, 2014, 21, 3687-3692.	1.2	17
214	Introduction to European comments on "Medullary Thyroid Cancer: management guidelines of the American Thyroid Association― Thyroid Research, 2013, 6, S1.	0.7	1
215	Results and summary of voting among the audience during presentation and discussion of Medullary Thyroid Carcinoma clinical guidelines prepared by American Thyroid Association. Thyroid Research, 2013, 6, S12.	0.7	4
216	Selenium supplementation for patients with Graves" $i^{1/2}$ hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials, 2013, 14, 119.	0.7	57

#	Article	IF	Citations
217	Central Hypothyroidism and Its Replacement Have a Significant Influence on Cardiovascular Risk Factors in Adult Hypopituitary Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3802-3810.	1.8	45
218	Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. European Journal of Internal Medicine, 2013, 24, 714-720.	1.0	104
219	Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease. Thyroid Research, 2013, 6, 11.	0.7	9
220	Subclinical hypothyroidism in pregnancy: to treat or not to treat. Endocrine, 2013, 44, 555-556.	1.1	2
221	Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement. Thyroid, 2013, 23, 1211-1225.	2.4	152
222	Fabry disease in children: agalsidaseâ€beta enzyme replacement therapy. Clinical Genetics, 2013, 83, 432-438.	1.0	42
223	Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak. European Journal of Endocrinology, 2013, 168, 733-743.	1.9	14
224	Careful Assessment of Maternal Thyroid Function Can Prevent Cases of Fetal Goitrous Hypothyroidism. Fetal Diagnosis and Therapy, 2013, 34, 66-68.	0.6	1
225	Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood. European Journal of Endocrinology, 2012, 166, 593-600.	1.9	5
226	Overall and cause-specific mortality in GH-deficient adults on GH replacement. European Journal of Endocrinology, 2012, 166, 1069-1077.	1.9	115
227	Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. European Journal of Endocrinology, 2012, 166, 247-253.	1.9	112
228	Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. JIMD Reports, 2012, 8, 51-56.	0.7	9
229	Is Thyroid Autoimmunity per se a Determinant of Quality of Life in Patients with Autoimmune Hypothyroidism?. European Thyroid Journal, 2012, 1, 186-192.	1.2	59
230	The metabolic consequences of thyroxine replacement in adult hypopituitary patients. Pituitary, 2012, 15, 495-504.	1.6	15
231	Further Thoughts on the Diagnosis and Diagnostic Criteria for Thyroid Storm. Thyroid, 2012, 22, 1094-1095.	2.4	19
232	Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry. Molecular Genetics and Metabolism, 2012, 105, 443-449.	0.5	58
233	Similar Clinical Features Among Patients with Severe Adult Growth Hormone Deficiency Diagnosed with Insulin Tolerance Test or Arginine or Glucagon Stimulation Tests. Endocrine Practice, 2012, 18, 325-334.	1.1	13
234	Mannose 6-Phosphate Receptor and Sortilin Mediated Endocytosis of \hat{l}_{\pm} -Galactosidase A in Kidney Endothelial Cells. PLoS ONE, 2012, 7, e39975.	1.1	26

#	Article	IF	CITATIONS
235	Thyroid cancer in Denmark 1943–2008, before and after iodine supplementation. International Journal of Cancer, 2012, 131, 2360-2366.	2.3	99
236	Thyroid effects of endocrine disrupting chemicals. Molecular and Cellular Endocrinology, 2012, 355, 240-248.	1.6	504
237	Antithyroid drug-induced fetal goitrous hypothyroidism. Nature Reviews Endocrinology, 2011, 7, 396-406.	4.3	52
238	Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin- $\hat{l^2}$ and inhibited by growth hormone releasing hormone and somatostatin. Growth Hormone and IGF Research, 2011, 21, 134-139.	0.5	12
239	Endocrine disorders in pregnancy: Physiological and hormonal aspects of pregnancy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 875-884.	2.2	70
240	Diagnostic dilemma: A young woman with Fabry disease symptoms, no family history, and a "sequencing crypticâ€Î±-galactosidase a large deletion. Molecular Genetics and Metabolism, 2011, 104, 314-318.	0.5	11
241	Fabry Disease and Early Stroke. Stroke Research and Treatment, 2011, 2011, 1-7.	0.5	19
242	Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients $\hat{a} \in \text{``AR}$ Randomized Placebo-Controlled Trial. PLoS ONE, 2011, 6, e21224.	1.1	12
243	Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease. PLoS ONE, 2011, 6, e25065.	1.1	96
244	Comment on "intrauterine diagnosis and management of fetal goiter: A case reportâ€, Journal of Clinical Ultrasound, 2011, 39, 276-278.	0.4	0
245	Pegylated Long-Acting Human Growth Hormone Possesses a Promising Once-Weekly Treatment Profile, and Multiple Dosing Is Well Tolerated in Adult Patients with Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 681-688.	1.8	29
246	Response: The Benefits of Invasive Treatment of Fetal Goitrous Hypothyroidism in Maternal Graves' Disease. Thyroid, 2011, 21, 932-933.	2.4	0
247	Lessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY. Hormone Research in Paediatrics, 2011, 76, 33-38.	0.8	18
248	Do Thyroid Disrupting Chemicals Influence Foetal Development during Pregnancy?. Journal of Thyroid Research, 2011, 2011, 1-14.	0.5	37
249	Challenges in Interpretation of Thyroid Function Tests in Pregnant Women with Autoimmune Thyroid Disease. Journal of Thyroid Research, 2011, 2011, 1-7.	0.5	30
250	Graves' Disease in Two Pregnancies Complicated by Fetal Goitrous Hypothyroidism: Successful <i>In Utero</i> Treatment with Levothyroxine. Thyroid, 2011, 21, 75-81.	2.4	24
251	Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?. Nutrition and Metabolism, 2010, 7, 72.	1.3	15
252	Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. Clinical Endocrinology, 2010, 73, 95-101.	1.2	39

#	Article	IF	CITATIONS
253	Autoimmunity in differentiated thyroid cancer: Significance and related clinical problems. Hormones, 2010, 9, 109-117.	0.9	74
254	Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. European Journal of Endocrinology, 2010, 162, 685-694.	1.9	40
255	Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease. European Journal of Endocrinology, 2010, 162, 677-684.	1.9	27
256	GH and IGF1 levels are positively associated with musculotendinous collagen expression: experiments in acromegalic and GH deficiency patients. European Journal of Endocrinology, 2010, 163, 853-862.	1.9	49
257	Childhood Exposure to Phthalates: Associations with Thyroid Function, Insulin-like Growth Factor I, and Growth. Environmental Health Perspectives, 2010, 118, 1458-1464.	2.8	249
258	Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. European Journal of Endocrinology, 2010, 162, 161-167.	1.9	163
259	Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. European Journal of Heart Failure, 2010, 12, 535-540.	2.9	75
260	Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry. Genetics in Medicine, 2010, 12, 703-712.	1,1	65
261	Cardiovascular and Cerebrovascular Events in Temporal Relationship to Intravenous Glucocorticoid Pulse Therapy in Patients with Severe Endocrine Ophthalmopathy. Thyroid, 2009, 19, 1431-1432.	2.4	32
262	Is increase in bone mineral content caused by increase in skeletal muscle mass/strength in adult patients with GH-treated GH deficiency? A systematic literature analysis. European Journal of Endocrinology, 2009, 161, 213-221.	1.9	17
263	Is the treatment of subclinical hypothyroidism beneficial?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 86-87.	2.9	10
264	Association of Thyroid Gland Volume, Serum Insulin-Like Growth Factor-I, and Anthropometric Variables in Euthyroid Prepubertal Children. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4031-4035.	1.8	28
265	From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum – a KIMS analysis. European Journal of Endocrinology, 2009, 161, S75-S83.	1.9	27
266	Narrow intra-individual variation of maternal thyroid function in pregnancy based on a longitudinal study on 132 women. European Journal of Endocrinology, 2009, 161, 903-910.	1.9	59
267	Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain, 2009, 145, 237-245.	2.0	63
268	Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination. Quality of Life Research, 2009, 18, 483-496.	1.5	84
269	Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined devangement of the combined dev	0.7	13
270	Hypothyroidism is associated with signs of endothelial dysfunction despite 1â€year replacement therapy with levothyroxine. Clinical Endocrinology, 2009, 70, 932-937.	1,2	19

#	Article	IF	Citations
271	Autonomic skin responses in females with Fabry disease. Journal of the Peripheral Nervous System, 2009, 14, 159-164.	1.4	21
272	lodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats. Autoimmunity, 2009, 42, 131-138.	1.2	15
273	Environmental chemicals and thyroid function: an update. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 385-391.	1.2	118
274	Radioiodine treatment for non-toxic goitre. F1000 Medicine Reports, 2009, 1, .	2.9	1
275	Does the type and severity of brain injury predict hypothalamo–pituitary dysfunction? Does post-traumatic hypopituitarism predict worse outcome?. Pituitary, 2008, 11, 255-261.	1.6	33
276	Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing. Quality of Life Research, 2008, 17, 1009-1017.	1.5	65
277	Immunohistochemical staining for thyroid peroxidase (TPO) of needle core biopsies in the diagnosis of scintigraphically cold thyroid nodules. Clinical Endocrinology, 2008, 68, 996-1001.	1.2	13
278	Elevated third-trimester haemoglobin A1c predicts preterm delivery in type 1 diabetes. Journal of Diabetes and Its Complications, 2008, 22, 297-302.	1.2	43
279	Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Molecular Genetics and Metabolism, 2008, 93, 112-128.	0.5	442
280	GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables. European Journal of Endocrinology, 2008, 159, 825-832.	1.9	13
281	Morbidity and GH deficiency: a nationwide study European Journal of Endocrinology, 2008, 158, 447-457.	1.9	40
282	Reduced Parietooccipital White Matter Glutamine Measured by Proton Magnetic Resonance Spectroscopy in Treated Graves' Disease Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3192-3198.	1.8	12
283	Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2729-2736.	1.8	50
284	Which Domains of Thyroid-Related Quality of Life Are Most Relevant? Patients and Clinicians Provide Complementary Perspectives. Thyroid, 2007, 17, 647-654.	2.4	78
285	Distribution of α-Galactosidase A in Normal Human Kidney and Renal Accumulation and Distribution of Recombinant α-Galactosidase A in Fabry Mice. Journal of the American Society of Nephrology: JASN, 2007, 18, 698-706.	3.0	40
286	Interactions Between Growth Hormone and the Thyroid Gland - with Special Reference to Biochemical Diagnosis. Current Medicinal Chemistry, 2007, 14, 2783-2788.	1.2	15
287	Clinical Implications of Residual Growth Hormone (GH) Response to Provocative Testing in Adults with Severe GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2604-2609.	1.8	22
288	Factors Influencing the Adrenocorticotropin Test: Role of Contemporary Cortisol Assays, Body Composition, and Oral Contraceptive Agents. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1326-1333.	1.8	124

#	Article	IF	CITATIONS
289	Posttraumatic Hypopituitarism Is Associated with an Unfavorable Body Composition and Lipid Profile, and Decreased Quality of Life 12 Months after Injury. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3861-3868.	1.8	77
290	Thyroid and Leptin. Thyroid, 2007, 17, 413-419.	2.4	96
291	Mortality and GH deficiency: a nationwide study. European Journal of Endocrinology, 2007, 157, 9-18.	1.9	100
292	Bridging Provocative Tests and Clinical Manifestations of Growth Hormone Deficiency in Adults. Hormone Research in Paediatrics, 2007, 68, 57-58.	0.8	1
293	Metabolic Effects of Growth Hormone. , 2007, , 477-484.		1
294	Treatment of Hypothyroidism in Elderly Patients and in Patients with Cardiac Disease. Thyroid, 2007, 17, 619-624.	2.4	28
295	Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genetics in Medicine, 2007, 9, 812-818.	1.1	47
296	285 ABNORMALITIES IN SMALL FIBRE STRUCTURE AND FUNCTION IN FEMALE FABRY PATIENTS. European Journal of Pain, 2007, 11, S126-S126.	1.4	0
297	Prevalence and predictive factors of post-traumatic hypopituitarism. Clinical Endocrinology, 2007, 67, 193-201.	1.2	143
298	Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study. Clinical Endocrinology, 2007, 67, 070630051835004-???.	1.2	91
299	Relationship between genotype and phenotype in 26 Danish patients with Fabry disease. Acta Paediatrica, International Journal of Paediatrics, 2007, 91, 118-118.	0.7	0
300	Affective symptoms and cognitive functions in the acute phase of Graves' thyrotoxicosis. Psychoneuroendocrinology, 2007, 32, 36-43.	1.3	77
301	Signs of maternal vascular dysfunction precede preeclampsia in women with type 1 diabetes. Journal of Diabetes and Its Complications, 2007, 21, 288-293.	1.2	29
302	What is the optimal follow-up strategy for patients with papillary thyroid microcarcinoma?. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 426-427.	2.9	0
303	Small-fibre neuropathy in female Fabry patients: reduced allodynia and skin blood flow after topical capsaicin. Journal of the Peripheral Nervous System, 2006, 11, 119-125.	1.4	35
304	Quality of life in patients with benign thyroid disorders. A review. European Journal of Endocrinology, 2006, 154, 501-510.	1.9	184
305	Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults – a KIMS database analysis. European Journal of Endocrinology, 2006, 155, 79-90.	1.9	125
306	Incidence of GH deficiency – a nationwide study. European Journal of Endocrinology, 2006, 155, 61-71.	1.9	94

#	Article	IF	CITATIONS
307	Effect on Muscles of Long-Term Treatment with Growth Hormone (GH) in Adults with GH Deficiency: KIMS Data and Review of the Literature. Hormone Research in Paediatrics, 2006, 66, 89-92.	0.8	2
308	Environmental chemicals and thyroid function. European Journal of Endocrinology, 2006, 154, 599-611.	1.9	430
309	Growth Hormone Replacement Therapy in Adults: Responsiveness Related to Life Quality., 2006,, 237-248.		0
310	Estrogen Replacement in Women of Fertile Years with Hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5964-5969.	1.8	53
311	Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. European Journal of Endocrinology, 2005, 152, 719-726.	1.9	16
312	Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5627-5631.	1.8	156
313	Isolated growth hormone (GH) deficiency in adult patients: Baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Hormone and IGF Research, 2005, 15, 349-359.	0.5	84
314	Impaired health-related quality of life in Graves' disease. A prospective study. European Journal of Endocrinology, 2004, 151, 549-555.	1.9	87
315	Thyrotropin-Releasing Hormone Stimulation Test in Patients with Pituitary Pathology. Hormone Research in Paediatrics, 2004, 61, 53-57.	0.8	30
316	Neonatal stimulation of the thyroid gland with iodine or suppression during adolescence with triiodothyronine changes the prevalence of autoimmune thyroiditis in BB rats. European Journal of Endocrinology, 2004, 151, 375-382.	1.9	5
317	Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Hormone and IGF Research, 2004, 14, 51-58.	0.5	44
318	Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. Thyroid, 2003, 13, 3-3.	2.4	1,037
319	A Population-Based Study of Thyroid Function after Radiotherapy and Chemotherapy for a Childhood Brain Tumor. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 136-140.	1.8	100
320	Circulating leptin and thyroid dysfunction. European Journal of Endocrinology, 2003, 149, 257-271.	1.9	138
321	Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotoxic Graves' disease. Neurology, 2003, 60, 142-145.	1.5	34
322	Serum thyroglobulin as a marker of thyroid neoplasms after childhood cancer. Acta Paediatrica, International Journal of Paediatrics, 2003, 92, 1284-1290.	0.7	8
323	Fabry Disease – A Metabolic Disorder with a Challenge for Endocrinologists?. Hormone Research in Paediatrics, 2002, 58, 259-265.	0.8	2
324	An audit of the insulin-tolerance test in 255 patients with pituitary disease. European Journal of Endocrinology, 2002, 147, 41-47.	1.9	34

#	Article	IF	Citations
325	Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. European Journal of Endocrinology, 2002, 146, 67-74.	1.9	75
326	Fabry disease: a new challenge in endocrinology and metabolism?. European Journal of Endocrinology, 2002, 146, 741-742.	1.9	2
327	Immune function during GH treatment in GH-deficient adults: an 18-month randomized, placebo-controlled, double-blinded trial. Clinical Endocrinology, 2002, 57, 787-792.	1.2	11
328	lodine and Cancer. Thyroid, 2001, 11, 483-486.	2.4	159
329	Hydrogen peroxide-induced production of a 40ÂkDa immunoreactive thyroglobulin fragment in human thyroid cells: the onset of thyroid autoimmunity?. Biochemical Journal, 2001, 360, 557-562.	1.7	36
330	Thyroid function in survivors of childhood acute lymphoblastic leukaemia: the significance of prophylactic cranial irradiation. Clinical Endocrinology, 2001, 55, 21-25.	1.2	39
331	The Influence of Growth Hormone Deficiency, Growth Hormone Replacement Therapy, and Other Aspects of Hypopituitarism on Fracture Rate and Bone Mineral Density. Journal of Bone and Mineral Research, 2001, 16, 398-405.	3.1	233
332	Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria. Diabetes Care, 2001, 24, 1739-1744.	4. 3	201
333	Healthcare Consumption Decreases in Parallel with Improvements in Quality of Life during GH Replacement in Hypopituitary Adults with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5277-5281.	1.8	73
334	Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study ¹ . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 117-123.	1.8	533
335	Thyroperoxidase (TPO) immunostaining of the solitary cold thyroid nodule. Clinical Endocrinology, 2000, 53, 161-169.	1.2	42
336	Growth hormone deficiency and replacement in elderly hypopituitary adults. Clinical Endocrinology, 2000, 53, 281-289.	1.2	70
337	Free and protein bound leptin are distinct and independently controlled factors in energy regulation. Diabetologia, 2000, 43, 438-442.	2.9	72
338	Thyrocyte-interleukin-1 interactions. Experimental and Clinical Endocrinology and Diabetes, 2000, 108, 67-71.	0.6	25
339	Thyrotropin Stimulates Specifically the Expression of the Autoantibody Binding Domains of the Thyroperoxidase Molecule. Autoimmunity, 1999, 29, 323-331.	1.2	12
340	Pathogenic and clinical aspects of Graves' disease. Experimental and Clinical Endocrinology and Diabetes, 1999, 107, S71-S74.	0.6	0
341	The Effects of Treatment and the Individual Responsiveness to Growth Hormone (GH) Replacement Therapy in 665 GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3929-3935.	1.8	149
342	Intestinal Adsorption of Levothyroxine by Antacids and Laxatives: Case Stories andin vitroExperiments. Basic and Clinical Pharmacology and Toxicology, 1999, 84, 107-109.	0.0	38

#	Article	IF	Citations
343	Co-existence of osteogenesis imperfecta and hyperparathyroidism. Journal of Endocrinological Investigation, 1999, 22, 547-550.	1.8	4
344	Antithyroid drug therapy: predictive parameters. Zeitschrift Für ÃÞtliche Fortbildung Und QualitÃÞssicherung, 1999, 93 Suppl 1, 53-5.	0.2	0
345	The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Clinical Endocrinology, 1998, 49, 589-595.	1.2	41
346	Lack of thyroglobulin synthesis as an indicator of early random dedifferentiation of the Fischer rat thyroid cell line FRTL-5. Scandinavian Journal of Clinical and Laboratory Investigation, 1998, 58, 529-536.	0.6	11
347	The Effects of Interleukin- $1\hat{l}^2$ (IL- $1\hat{l}^2$) on Human Thyrocyte Functions Are Counteracted by the IL-1 Receptor Antagonist*. Endocrinology, 1997, 138, 2043-2048.	1.4	24
348	Human thyroid epithelial cells cultured in monolayers. I. Decreased thyroglobulin and cAMP response to TSH in 12-week-old secondary and tertiary cultures. Molecular and Cellular Endocrinology, 1996, 116, 165-172.	1.6	22
349	Human thyroid epithelial cells cultured in monolayers. II. Influence of serum on thyroglobulin and cAMP production. Molecular and Cellular Endocrinology, 1996, 116, 173-179.	1.6	10
350	Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Clinical Chemistry, 1996, 42, 160-163.	1.5	79
351	Long-Term Observation of Serum Thyroglobulin after Resection of Nontoxic Goiter and Relation to Ultrasonographically Demonstrated Relapse. World Journal of Surgery, 1996, 20, 351-357.	0.8	12
352	Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Clinical Chemistry, 1996, 42, 160-3.	1.5	17
353	Human thyroglobulin reference material (CRM 457). 1st Part: Assessment of homogeneity, stability and immunoreactivity. Annales De Biologie Clinique, 1996, 54, 337-42.	0.2	28
354	Human thyroglobulin reference material (CRM 457). 2nd Part: Physicochemical characterization and certification. Annales De Biologie Clinique, 1996, 54, 343-8.	0.2	29
355	Assessment of the Influence of Thyroglobulin (Tg) Autoantibodies and Other Interfering Factors on the Use of Serum Tg as Tumor Marker in Differentiated Thyroid Carcinoma. Thyroid, 1995, 5, 165-170.	2.4	44
356	Thyroid function and autoimmunity in pernicious anemia before and during cyanocobalamin treatment. Journal of Endocrinological Investigation, 1995, 18, 91-97.	1.8	34
357	Influence of tumour necrosis factor- \hat{l}_{\pm} , tumour necrosis factor- \hat{l}^2 and interferon- \hat{l}^3 , separately and added together with interleukin-1 \hat{l}^2 , on the function of cultured human thyroid cells. Journal of Endocrinology, 1994, 143, 359-365.	1.2	56
358	Bispecific thyroglobulin and thyroperoxidase autoantibodies in patients with various thyroid and autoimmune diseases Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1404-1409.	1.8	27
359	Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease Journal of Clinical Endocrinology and Metabolism, 1994, 78, 98-102.	1.8	158
360	Nitric Oxide Production is not involved in the Effects of Interleukin- $1\hat{1}^2$ on CAMP, Thyroglobulin and Interleukin-6 in TSH-Stimulated Human Thyroid Cells. Autoimmunity, 1994, 19, 239-245.	1.2	13

#	Article	IF	CITATIONS
361	Influence of thyroxine treatment on thyroid size and antiâ€thyroid peroxidase antibodies in Hashimoto's thyroiditis. Clinical Endocrinology, 1991, 35, 235-238.	1.2	60
362	Thyroid function tests in patients with acquired immune deficiency syndrome and healthy HIV1-positive out-patients. European Journal of Clinical Investigation, 1991, 21, 59-63.	1.7	17
363	Evidence for acute release of thyroid peroxidase during subtotal thyroidectomy. European Journal of Endocrinology, 1991, 124, 661-665.	1.9	2
364	Anti-Thyroid Peroxidase Antibodies in Thyroid Disorders and Non-Thyroid Autoimmune Diseases. Autoimmunity, 1991, 9, 245-254.	1.2	66
365	Anti-Thyroid Peroxidase Antibodies During Pregnancy and Postpartum. Relation to Postpartum Thyroiditis. Autoimmunity, 1990, 6, 211-214.	1.2	36
366	Differential effects of interleukin $1\hat{l}\pm$ and $1\hat{l}^2$ on cultured human and rat thyroid epithelial cells. European Journal of Endocrinology, 1990, 122, 520-526.	1.9	22
367	Serum thyroglobulin during the menstrual cycle, during pregnancy, and post partum. European Journal of Endocrinology, 1989, 121, 168-173.	1.9	43
368	Suppressed Natural Killer Cell Activity in Patients with Euthyroid Graves' Ophthalmopathy. Autoimmunity, 1989, 2, 291-298.	1.2	5
369	The variable intrafamiliar expressivity in Pendred's syndrome. Clinical Otolaryngology, 1989, 14, 395-399.	0.6	20
370	Relationship between serum thyroglobulin, thyroid volume and serum TSH in healthy non-goitrous subjects and the relationship to seasonal variations in iodine intake. Thyroidology, 1989, 1, 115-8.	0.1	9
371	Interleukin-1 affects the function of cultured human thyroid cells. Allergy: European Journal of Allergy and Clinical Immunology, 1988, 43, 435-441.	2.7	52
372	European interlaboratory comparison of serum thyroglobulin measurement. Journal of Endocrinological Investigation, 1988, 11, 175-181.	1.8	63
373	Serum thyroglobulin in chronic renal failure—effects of haemodialysis. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 35-40.	0.6	2
374	Thyroid function in patients with breast cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 553-556.	0.9	55
375	IgG SUBCLASS DISTRIBUTION OF THYROID AUTOANTIBODIES: A  FINGERPRINT' OF AN INDIVIDUAL'S RESPO TO THYROGLOBULIN AND THYROID MICROSOMAL ANTIGEN. Clinical Endocrinology, 1987, 26, 335-346.	ONSE	42
376	COMPARISON BETWEEN HOMOGENEOUS PHASE RADIOâ€ASSAY AND ENZYMEâ€LINKED IMMUNOSORBENT ASSAY FOR MEASUREMENT OF ANTITHYROGLOBULIN ANTIBODY CONTENT IN SERUM. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section C, Immunology, 1986, 94C, 33-38.	0.2	0
377	INCREASED FREQUENCY OF GOITRE IN EPILEPTIC PATIENTS ON LONGâ€TERM PHENYTOIN OR CARBAMAZEPINE TREATMENT. Clinical Endocrinology, 1985, 23, 423-429.	1.2	49
378	Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo. Journal of Endocrinological Investigation, 1985, 8, 571-576.	1.8	47

#	Article	IF	Citations
379	Heterogeneity of Autoimmune Thyroiditis. Allergy: European Journal of Allergy and Clinical Immunology, 1984, 39, 239-247.	2.7	13
380	ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETERMINATION OF THYROGLOBULIN AUTOANTIBODIES. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section C, Immunology, 1984, 92C, 377-382.	0.2	5
381	Discrepancy between Haemagglutination and Radioimmunological Techniques for Measurement of Serum Thyroglobulin Autoantibodies. Allergy: European Journal of Allergy and Clinical Immunology, 1983, 38, 49-56.	2.7	12
382	Serum Thyroglobulin and Thyroglobulin Autoantibodies in Thyroid Diseases. Allergy: European Journal of Allergy and Clinical Immunology, 1983, 38, 369-387.	2.7	35
383	SERUM THYROGLOBULIN IN ACUTE AND CHRONIC LIVER DISEASE. Clinical Endocrinology, 1983, 19, 231-237.	1.2	12
384	Influence of thyroid substitution therapy and thyroid autoantibodies on the value of serum thyroglobulin in recurring thyroid cancer. Cancer, 1983, 51, 2240-2244.	2.0	33
385	THE ACUTE CHANGES IN THYROID STIMULATING IMMUNOGLOBULINS, THYROGLOBULIN AND THYROGLOBULIN ANTIBODIES FOLLOWING SUBTOTAL THYROIDECTOMY*. Clinical Endocrinology, 1982, 16, 235-242.	1.2	33
386	Serum thyroglobulin and its autoantibody following subtotal thyroid resection of Graves' disease. European Journal of Clinical Investigation, 1982, 12, 203-208.	1.7	14
387	Thyroid Stimulating Antibodies, Thyroglobulin Antibodies and Serum Proteins during Treatment of Graves? Disease with Radioiodine or Propylthouracil. Allergy: European Journal of Allergy and Clinical Immunology, 1982, 37, 161-167.	2.7	22
388	Circulating Immune Complexes and Complement-fixing Antibodies in Patients with Varicella-Zoster Infection: Relationship to Début of the Disease. Scandinavian Journal of Infectious Diseases, 1980, 12, 21-26.	1.5	9
389	SEQUENTIAL CHANGES IN SERUM THYROGLOBULIN (Tg) AND ITS AUTOANTIBODIES (TgAb) FOLLOWING SUBTOTAL THYROIDECTOMY OF PATIENTS WITH PREOPERATIVELY DETECTABLE TgAb. Clinical Endocrinology, 1980, 12, 29-38.	1.2	38
390	An improved co-precipitation assay for determination of thyroglobulin antibodies. Scandinavian Journal of Clinical and Laboratory Investigation, 1980, 40, 37-43.	0.6	47
391	Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. European Journal of Endocrinology, 1980, 95, 328-334.	1.9	61
392	Variations in Plasma Protein Concentrations in Individuals with Ulcerative Colitis: Analytical and Biological Factors. Scandinavian Journal of Clinical and Laboratory Investigation, 1979, 39, 495-502.	0.6	9
393	THYROGLOBULIN OF VARYING MOLECULAR SIZES WITH DIFFERENT DISAPPEARANCE RATES IN PLASMA FOLLOWING SUBTOTAL THYROIDECTOMY. Clinical Endocrinology, 1978, 9, 205-214.	1.2	52
394	Purification of human thyroglobulin for radioimmunoassay and testing by ultracentrifugal analysis and immunoelectrophoresis. Journal of Immunological Methods, 1978, 21, 295-303.	0.6	27
395	Paraganglioma of the basis cranii due to somatic mutations ind SDHB and PTEN genes. Endocrine Abstracts, 0, , .	0.0	0
396	Treatment regimens affecting glucose metabolism and gastrointestinal hormones in acromegaly: A descriptive study. Endocrine Abstracts, 0, , .	0.0	0

#	Article	IF	CITATIONS
397	Pituitary function after transsphenoidal surgery including measurement of basal morning cortisol as predictor of adrenal insufficiency. Endocrine Abstracts, 0, , .	0.0	0
398	The Effects of Interleukin- $1\hat{l}^2$ (IL- $1\hat{l}^2$) on Human Thyrocyte Functions Are Counteracted by the IL-1 Receptor Antagonist. , 0, .		3
399	Method-specific serum cortisol responses to the ACTH test: comparison of two generations of Roche automated immunoassays using polyclonal vs MABs. Endocrine Abstracts, 0, , .	0.0	4
400	Semen quality in uncontrolled acromegalic patients with hypogonadism. Endocrine Abstracts, 0, , .	0.0	0
401	A multicentre, randomized, open-label, Phase IV study investigating management of pasireotide-associated hyperglycaemia with incretin-based therapy or insulin in patients with acromegaly or Cushing's disease (CD). Endocrine Abstracts, 0, , .	0.0	0
402	Variability of momentarily measured fatigue in patients with pituitary insufficiency receiving hydrocortisone replacement therapy. Endocrine Abstracts, 0 , , .	0.0	0
403	A randomized-controlled trial of tesomet resulted in significant weight loss in hypopituitary patients with hypothalamic obesity. Endocrine Abstracts, 0, , .	0.0	0
404	The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments. Endocrine Abstracts, 0, , .	0.0	0
405	Acromegaly is associated with reduced socioeconomic status and more so in female patients: A nationwide population-based study. Endocrine Abstracts, 0, , .	0.0	0
406	Levoketoconazole in the treatment of endogenous Cushing's syndrome: Extended evaluation phase results of the SONICS study. Endocrine Abstracts, 0, , .	0.0	1